UNIVERSAL PHARMA
ActiveSummary
UNIVERSAL PHARMA has been active since 1992 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €23.1m and a net result of €2.0m. Equity is growing by ~8.1% per year across the filed fiscal years. Its solvency ranks better than 84% of 4913 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is < 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
07-07
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
03-07
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
28-08
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 28 days late
2023
26-07
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
18-08
NBB filing
Annual accounts filed
fiscal year 2021 · full schema · 18 days late
2021
31-12
Financial
Highest result since 2018net €2.2m ▲0.3%
Operating result €2.5m, net result €2.2m, both a record.
09-08
NBB filing
Annual accounts filed
fiscal year 2020 · full schema · 9 days late
2020
12-08
NBB filing
Annual accounts filed
fiscal year 2019 · full schema · 12 days late
2019
31-12
Financial
Weakest financial yearnet €970,335 ▼18.3%
Net result drops to €970,335, the lowest in the series; recovery starts the following year.
08-08
NBB filing
Annual accounts filed
fiscal year 2018 · full schema · 8 days late
2018
02-08
NBB filing
Annual accounts filed
fiscal year 2017 · full schema · 2 days late
2017
17-07
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 14 acts read
About the unread acts
We know of 14 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.